据印度代购了解,2018年，“革命性”的抗癌药物-拉罗替尼在美国获批上市，这款新型的抗癌药物每年可以帮助成千上万的人，这些患者中超过75％的患者反应良好，肿瘤缩小或消失。无论是成人还是儿童，拉罗替尼已经给各类晚期癌症患者带来了新的希望，2020年这款被誉为“治愈系”的抗癌药拉罗替尼针对成人实体瘤的临床试验终于正式在国内开始招募患者了！这意味着，中国患者也终于有机会免费用上这款美国的抗癌“特药”！而近日，再次得到好消息，拉罗替尼的儿童肿瘤临床试验也正式开始招募患者了，中国的孩子们也终于等到了这款救命新药！

 In 2018, the "revolutionary" cancer drug larotinib was approved for sale in the United States. This new cancer drug could help thousands of people every year, and more than 75 percent of these patients respond well, with tumors shrinking or disappearing, according to Dabuy India. Larlotinib has brought new hope to patients with advanced cancer of all kinds, including adults and children. The clinical trial of larlotinib, which is hailed as a "cure line", will finally start in China in 2020. This means that Chinese patients finally have the opportunity to use this American anti-cancer "special drug" for free! Chinese children are finally waiting for larotinib, a life-saving drug, as the clinical trial of larotinib in children has begun to recruit patients.

　　据印度代购了解,儿童肿瘤是所有家庭的痛，而其中的儿童脑瘤更是让父母感到无助和绝望。和儿童常见的白血病和淋巴瘤相比，脑瘤的进展速度极快，并且在早期就会沿大脑中的白质蔓延，很难确定肿瘤实际扩散的程度，这意味着要想完全切除几乎是不可能的。更不幸的是，大脑存在一层血-脑屏障，一般的药物难以到达，近三十年来没有一款新药获批，因此儿童肿瘤患儿的家庭常常陷入绝境。拉罗替尼的上市，为儿童脑瘤患者带来了新的希望。

　　据印度代购了解,据统计，NTRK融合在脑肿瘤出现的频率在儿童和成人中差异较大，在3~40%之间，多形性胶质母细胞瘤中最常见的是NTRK2融合。FDA基于卓越的临床数据批准拉罗替尼上市！在TRK融合癌患者的三项大型实体瘤临床试验汇总数据显示，针对17类实体瘤，拉罗替尼的总缓解率（ORR）高达75％，其中22％的患者完全缓解。

According to Daigou India, according to statistics, the frequency of NTRK fusion in brain tumors varies greatly between children and adults, ranging from 3 to 40%. The most common one in glioblastoma multiforme is NTRK2 fusion. FDA approves Larlotinib based on Superior Clinical Data! Pooled data from three large solid tumor trials in patients with TRK fusion cancer showed that larotinib achieved an overall response rate (ORR) of 75% for 17 types of solid tumors, with 22% of patients achieving complete response.